Harrington D - Search Results

1

Allele-specific amplification in cancer revealed by SNP array analysis.

LaFramboise T, Weir BA, Zhao X, Beroukhim R, Li C, Harrington D, Sellers WR, Meyerson M. LaFramboise T, et al. Among authors: harrington d. PLoS Comput Biol. 2005 Nov;1(6):e65. doi: 10.1371/journal.pcbi.0010065. Epub 2005 Nov 25. PLoS Comput Biol. 2005. PMID: 16322765 Free PMC article.

2

PLASQ: a generalized linear model-based procedure to determine allelic dosage in cancer cells from SNP array data.

Laframboise T, Harrington D, Weir BA. Laframboise T, et al. Among authors: harrington d. Biostatistics. 2007 Apr;8(2):323-36. doi: 10.1093/biostatistics/kxl012. Epub 2006 Jun 20. Biostatistics. 2007. PMID: 16787995

3

Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis.

Schwede M, Spentzos D, Bentink S, Hofmann O, Haibe-Kains B, Harrington D, Quackenbush J, Culhane AC. Schwede M, et al. Among authors: harrington d. PLoS One. 2013;8(3):e57799. doi: 10.1371/journal.pone.0057799. Epub 2013 Mar 11. PLoS One. 2013. PMID: 23536770 Free PMC article.

4

The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer.

Schwede M, Waldron L, Mok SC, Wei W, Basunia A, Merritt MA, Mitsiades CS, Parmigiani G, Harrington DP, Quackenbush J, Birrer MJ, Culhane AC. Schwede M, et al. Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):509-519. doi: 10.1158/1055-9965.EPI-18-1359. Epub 2019 Dec 23. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 31871106 Free PMC article.

5

Efficiency of balanced treatment allocation for survival analysis.

Kalish LA, Harrington DP. Kalish LA, et al. Among authors: harrington dp. Biometrics. 1988 Sep;44(3):815-21. Biometrics. 1988. PMID: 3203130

6

A semiparametric estimate of treatment effects with censored data.

Xu R, Harrington DP. Xu R, et al. Among authors: harrington dp. Biometrics. 2001 Sep;57(3):875-85. doi: 10.1111/j.0006-341x.2001.00875.x. Biometrics. 2001. PMID: 11550940

7

New Guidelines for Statistical Reporting. Reply.

Harrington D. Harrington D. N Engl J Med. 2019 Oct 17;381(16):1597-1598. doi: 10.1056/NEJMc1911817. N Engl J Med. 2019. PMID: 31618558 No abstract available.

8

Effectiveness of extreme discordant sib pairs to detect oligogenic disease loci.

Rogus JJ, Harrington DP, Jorgenson E, Xu X. Rogus JJ, et al. Among authors: harrington dp. Genet Epidemiol. 1997;14(6):879-84. doi: 10.1002/(SICI)1098-2272(1997)14:6<879::AID-GEPI53>3.0.CO;2-J. Genet Epidemiol. 1997. PMID: 9433594

9

Learning from a Trial Stopped by a Data and Safety Monitoring Board.

Harrington D, Drazen JM. Harrington D, et al. N Engl J Med. 2018 May 24;378(21):2031-2032. doi: 10.1056/NEJMe1805123. N Engl J Med. 2018. PMID: 29791830 No abstract available.

10

I-SPY 2--A Glimpse of the Future of Phase 2 Drug Development?

Harrington D, Parmigiani G. Harrington D, et al. N Engl J Med. 2016 Jul 7;375(1):7-9. doi: 10.1056/NEJMp1602256. N Engl J Med. 2016. PMID: 27406345 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,178 results

Search Page